Alumis Inc
ALMS4.075USD
-0.055-1.33%
交易中 （美東）報價延遲15分鐘
221.71M總市值
虧損本益比TTM
關於 Alumis Inc 公司
Alumis Inc. 是一家臨牀階段的生物製藥公司。該公司開發了兩種酪氨酸激酶 2 (TYK2) 抑制劑：ESK-001，一種第二代抑制劑，該公司正在開發該抑制劑以最大限度地抑制靶標並優化耐受性，以及 A-005，一種中樞神經系統 (CNS) 滲透性分子。該公司建立了一系列分子，有可能作爲單一療法或聯合療法治療一系列免疫介導疾病。ESK-001 是一種變構 TYK2 抑制劑，用於治療斑塊狀銀屑病、系統性紅斑狼瘡和葡萄膜炎。A-005 是一種 CNS 滲透性變構 TYK2 抑制劑，可在 CNS 內提供 TYK2 抑制的治療益處，用於治療一系列神經炎症和神經退行性疾病。該公司擁有多項早期發現資產，例如其數據分析平臺確定的靶標，可用於治療免疫介導的適應症。其數據分析證明了中樞神經系統疾病中 TYK2 抑制的遺傳原理。
公司簡介
公司代碼ALMS
公司名稱Alumis Inc
上市日期Jun 28, 2024
CEOMr. Martin Babler
員工數量168
證券類型Ordinary Share
年結日Jun 28
公司地址280 East Grand Avenue
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編94080
電話16502316625
網址https://www.alumis.com/
公司代碼ALMS
上市日期Jun 28, 2024
CEOMr. Martin Babler
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Martin Babler
Mr. Martin Babler
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
106.45K
--
Mr. Mark Bradley
Mr. Mark Bradley
Chief Development Officer
Chief Development Officer
48.73K
+121.71%
Mr. Derrick Richardson
Mr. Derrick Richardson
Senior Vice President - People and Culture
Senior Vice President - People and Culture
42.80K
--
Mr. John R. Schroer
Mr. John R. Schroer
Chief Financial Officer
Chief Financial Officer
28.00K
--
Dr. Jorn Drappa, M.D., Ph.D.
Dr. Jorn Drappa, M.D., Ph.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
25.45K
--
Mr. Patrick (Pat) Machado, J.D.
Mr. Patrick (Pat) Machado, J.D.
Independent Director
Independent Director
7.06K
--
Ms. Lynn A. Tetrault, J.D.
Ms. Lynn A. Tetrault, J.D.
Independent Director
Independent Director
--
--
Dr. Srinivas Akkaraju, M.D., Ph.D.
Dr. Srinivas Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Roy C. Hardiman, J.D.
Mr. Roy C. Hardiman, J.D.
Chief Business and Strategy Officer
Chief Business and Strategy Officer
--
--
Mr. Alan B. Colowick, M.D.
Mr. Alan B. Colowick, M.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Martin Babler
Mr. Martin Babler
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
106.45K
--
Mr. Mark Bradley
Mr. Mark Bradley
Chief Development Officer
Chief Development Officer
48.73K
+121.71%
Mr. Derrick Richardson
Mr. Derrick Richardson
Senior Vice President - People and Culture
Senior Vice President - People and Culture
42.80K
--
Mr. John R. Schroer
Mr. John R. Schroer
Chief Financial Officer
Chief Financial Officer
28.00K
--
Dr. Jorn Drappa, M.D., Ph.D.
Dr. Jorn Drappa, M.D., Ph.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
25.45K
--
Mr. Patrick (Pat) Machado, J.D.
Mr. Patrick (Pat) Machado, J.D.
Independent Director
Independent Director
7.06K
--
收入明細
FY2025Q1
暫無數據
地區USD
名稱
營收
佔比
United States
17.39M
0.00%
業務
地區
暫無數據
股東統計
更新時間: 7月29日 週二
更新時間: 7月29日 週二
持股股東
股東類型
持股股東
持股股東
佔比
Foresite Capital Management, LLC
15.83%
Ayur Maya Capital Management Company, L.P.
15.77%
Samsara BioCapital, LLC
5.00%
VenBio Partners LLC
2.90%
Cormorant Asset Management, LP
2.24%
Other
58.26%
持股股東
持股股東
佔比
Foresite Capital Management, LLC
15.83%
Ayur Maya Capital Management Company, L.P.
15.77%
Samsara BioCapital, LLC
5.00%
VenBio Partners LLC
2.90%
Cormorant Asset Management, LP
2.24%
Other
58.26%
股東類型
持股股東
佔比
Private Equity
34.50%
Venture Capital
7.06%
Investment Advisor
5.68%
Hedge Fund
4.34%
Investment Advisor/Hedge Fund
2.14%
Individual Investor
0.64%
Bank and Trust
0.43%
Research Firm
0.34%
Sovereign Wealth Fund
0.21%
Other
44.65%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
149
53.14M
55.36%
+11.35M
2025Q1
136
45.24M
77.97%
+3.71M
2024Q4
112
45.08M
95.45%
+8.63M
2024Q3
90
35.83M
75.90%
+3.97M
2024Q2
36
30.85M
69.04%
+30.85M
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Foresite Capital Management, LLC
15.20M
15.83%
+5.22M
+52.25%
May 21, 2025
Ayur Maya Capital Management Company, L.P.
15.14M
15.77%
+4.49M
+42.21%
May 21, 2025
Samsara BioCapital, LLC
4.80M
5%
+1.53M
+46.99%
May 21, 2025
VenBio Partners LLC
2.79M
2.9%
--
--
Mar 31, 2025
Cormorant Asset Management, LP
2.15M
2.24%
--
--
Mar 31, 2025
SR One Capital Management, LP
1.96M
2.04%
--
--
Mar 31, 2025
Baker Bros. Advisors LP
1.56M
1.63%
--
--
Mar 31, 2025
Nextech Invest, Ltd.
1.48M
1.54%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.35M
1.41%
+300.30K
+28.57%
Mar 31, 2025
The Vanguard Group, Inc.
937.20K
0.98%
+99.01K
+11.81%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Invesco Nasdaq Biotechnology ETF
0.03%
iShares Micro-Cap ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.03%
iShares Biotechnology ETF
0.02%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
Avantis US Small Cap Equity ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
Global X Russell 2000 ETF
0.01%
查看更多
Invesco Nasdaq Biotechnology ETF
佔比0.03%
iShares Micro-Cap ETF
佔比0.03%
ProShares Ultra Nasdaq Biotechnology
佔比0.03%
iShares Biotechnology ETF
佔比0.02%
ProShares Hedge Replication ETF
佔比0.01%
iShares Russell 2000 Value ETF
佔比0.01%
Avantis US Small Cap Equity ETF
佔比0.01%
Proshares Ultra Russell 2000
佔比0.01%
ProShares UltraPro Russell2000
佔比0.01%
Global X Russell 2000 ETF
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
